Načítá se...
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
HER2-positive (HER2+) breast cancer accounts for 18%–20% of all breast cancer cases and has the second poorest prognosis among breast cancer subtypes. Trastuzumab, the first Food and Drug Administration-approved targeted therapy for breast cancer, established the era of personalized treatment for HE...
Uloženo v:
| Vydáno v: | Biochim Biophys Acta |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4261073/ https://ncbi.nlm.nih.gov/pubmed/25065528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbcan.2014.07.007 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|